METHOD OF DIFFERENTIATING MAMMALIAN PROGENITOR CELLS INTO INSULIN PRODUCING PANCREATIC ISLET CELLS

• US 20170045497A1
• Filed: 10/27/2016
• Published: 02/16/2017
• Est. Priority Date: 05/22/2008
• Status: Abandoned Application

• Current Assignee: Vesta Therapeutics, Inc.
• Original Assignee: Vesta Therapeutics, Inc.
• Inventors: RUIZ, Joseph Charles, HOYNOWSKI, Steven Michael
• Application Number:
  US15/336,783
• Publication Number:
  US 20170045497A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C12N 2500/30 Organic components
• CPC Class Codes: C12N 2500/36 Lipids
• CPC Class Codes: C12N 2500/90 Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2501/065 Modulators of histone acetylation
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2506/14 from hepatocytes
• CPC Class Codes: C12N 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 5/067 Hepatocytes
• CPC Class Codes: C12N 5/0676 Pancreatic cells
• CPC Class Codes: G01N 33/5014 for testing toxicity
• CPC Class Codes: G01N 33/5038 involving detection of metabolites per se
• CPC Class Codes: G01N 33/507 Pancreatic cells

Abstract

The invention relates to methods for differentiating progenitor cells into insulin producing pancreatic islet cells and compositions and methods for using such cells.

Claims

1-7. -7. (canceled)

8. A method for evaluating the toxicity of a compound in vitro, comprising:

(a) contacting a pancreatic β

islet-like cell differentiated from progenitor cells with the compound; and

(b) measuring the viability of the pancreatic β

islet-like cell,

wherein a decrease in viability in the presence of said compound compared to that in the absence of said compound indicates that said compound is toxic in vivo, and

wherein the differentiation comprises;

(i) incubating the progenitor cells in serum-free pre-induction media comprising sodium butyrate; and

, subsequently,

(ii) incubating the progenitor cell in induction media comprising knock-out replacement serum;

for a time sufficient to differentiate the progenitor cells into insulin producing pancreatic cells.

9. A method for evaluating the activity of a compound in vitro, comprising:

(a) contacting a metabolically active pancreatic β

islet-like cell differentiated from progenitor cells with the compound; and

(b) measuring the metabolic activity of the pancreatic β

islet-like cell,

wherein a decrease or increase in metabolic activity in the presence of the compound compared to that in the absence of the compound indicates that the compound has activity in vivo, and

wherein the differentiation comprises;

(i) incubating the progenitor cells in serum-free pre-induction media comprising sodium butyrate; and

, subsequently,

(ii) incubating the progenitor cell in induction media comprising knock-out replacement serum;

for a time sufficient to differentiate the progenitor cells into insulin producing pancreatic cells.